In COVID-19 clinical update #65, Daniel Griffin summarizes effects of non-pharmaceutical interventions, updated summer camp guidance from CDC, serology testing not recommended by FDA, antigen tests during a music event, inhibition of vaccine immunogenicity by methotrexate, phase 3 trial results for colchicine, and small airway disease as a post-acute sequelae.

In COVID-19 clinical update #64, Daniel Griffin covers new guidance from NY on day camps, mitigation and infection rates in schools, testing to sustain in person instruction, Moderna mRNA vaccine highly effective in adolescents, longer storage of Pfizer vaccine, FDA EUA for sotrovimab, and persistent illness in UK children.

In COVID-19 clinical update #63, Daniel Griffin reviews cases at child care facilities, estimates of mRNA vaccine effectiveness, risk of reinfection in university students, enhanced antibody generation with extended interval of mRNA vaccination, no benefit of convalescent plasma in hospitalized patients, and risk of clinical sequelae after acute infection.

In COVID-19 clinical update #61, Daniel Griffin reviews a modeling of future hospitalizations and deaths by vaccination rates and non pharmaceutical intervention scenarios, performance evaluation of rapid antigen tests, children making up a growing share of new cases, antibody response to mRNA vaccine in solid organ transplant recipients, and outcomes in hospitalized patients treated with tocilizumab.

In COVID-19 clinical update #56, Daniel Griffin notes increasing hospitalization in children and young adults, Pfizer vaccine efficacy results in 12-15 year olds, rapid self administered nucleic acid and antigen tests, mRNA vaccine efficacy in real world conditions, and improvement of long COVID after vaccination.

Alessandro Sette joins TWiV to discuss the role of T cells in COVID-19, the finding that amino acid changes in SARS-CoV-2 variants of concern have a negligible impact on T cell reactivity in convalescent patients and vaccinees, and whether a next generation vaccine should include more viral proteins than spike.

In COVID-19 clinical update #55, Daniel Griffin reviews recommendations for keeping transmission low in school settings, optimal testing strategies for schools and businesses, impact of vaccines on asymptomatic infections, vaccine safety in PASC patients, and early use of aspirin associated with decreased mortality.